Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 983
Filter
1.
PLoS Negl Trop Dis ; 18(4): e0012048, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38564496

ABSTRACT

BACKGROUND: Numerous studies indicate a potential protective role of helminths in diabetes mellitus (DM) progression. The complement system, vital for host defense, plays a crucial role in tissue homeostasis and immune surveillance. Dysregulated complement activation is implicated in diabetic complications. We aimed to investigate the influence of the helminth, Strongyloides stercoralis (Ss) on complement activation in individuals with type 2 DM (T2D). METHODOLOGY: We assessed circulating levels of complement proteins (C1q, C2, C3, C4, C4b, C5, C5a, and MBL (Lectin)) and their regulatory components (Factor B, Factor D, Factor H, and Factor I) in individuals with T2D with (n = 60) or without concomitant Ss infection (n = 58). Additionally, we evaluated the impact of anthelmintic therapy on these parameters after 6 months in Ss-infected individuals (n = 60). RESULTS: Ss+DM+ individuals demonstrated reduced levels of complement proteins (C1q, C4b, MBL (Lectin), C3, C5a, and C3b/iC3b) and complement regulatory proteins (Factor B and Factor D) compared to Ss-DM+ individuals. Following anthelmintic therapy, there was a partial reversal of these levels in Ss+DM+ individuals. CONCLUSION: Our findings indicate that Ss infection reduces complement activation, potentially mitigating inflammatory processes in individuals with T2D. The study underscores the complex interplay between helminth infections, complement regulation, and diabetes mellitus, offering insights into potential therapeutic avenues.


Subject(s)
Anthelmintics , Diabetes Mellitus, Type 2 , Helminths , Strongyloides stercoralis , Strongyloidiasis , Animals , Humans , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Complement Factor B , Complement Factor D/therapeutic use , Complement C1q , Strongyloidiasis/complications , Strongyloidiasis/drug therapy , Complement Activation , Anthelmintics/therapeutic use , Lectins
2.
Am J Trop Med Hyg ; 110(5): 961-964, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38531110

ABSTRACT

Co-occurrence of paracoccidioidomycosis and strongyloidiasis in immunosuppressed patients, particularly those infected with human T-lymphotropic virus type 1/2, is infrequent. We describe the case of a Peruvian farmer from the central jungle with human T-lymphotropic virus type 1/2 infection, with 2 months of illness characterized by respiratory and gastrointestinal symptoms associated with fever, weight loss, and enlarged lymph nodes. Strongyloides stercoralis and Paracoccidioides brasiliensis were isolated in sputum and bronchoalveolar lavage samples, respectively. The clinical evolution was favorable after the patient received ivermectin and amphotericin B. We hypothesize that autoinfestation by S. stercoralis in human T-lymphotropic virus type 1/2-infected patients may contribute to the disseminated presentation of Paracoccidioides spp. Understanding epidemiological context is crucial for suspecting opportunistic regional infections, particularly those that may coexist in immunosuppressed patients.


Subject(s)
HTLV-I Infections , Ivermectin , Paracoccidioidomycosis , Strongyloides stercoralis , Strongyloidiasis , Humans , Paracoccidioidomycosis/drug therapy , Paracoccidioidomycosis/complications , Paracoccidioidomycosis/diagnosis , Strongyloidiasis/drug therapy , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Male , HTLV-I Infections/complications , Animals , Ivermectin/therapeutic use , Strongyloides stercoralis/isolation & purification , Human T-lymphotropic virus 1/isolation & purification , Paracoccidioides/isolation & purification , Coinfection , HTLV-II Infections/complications , Immunocompromised Host , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Adult
3.
Travel Med Infect Dis ; 58: 102690, 2024.
Article in English | MEDLINE | ID: mdl-38246513

ABSTRACT

BACKGROUND: Imported strongyloidiasis in non-endemic countries has increasingly been diagnosed. The aim of the present study is to describe the main epidemiological and clinical characteristics of patients with imported strongyloidiasis attended in a referral International Health Unit and to detect trend changes over a 12-year period. METHODS: This is an observational retrospective study including all imported strongyloidiasis cases seen at the International Health Unit Vall d'Hebron-Drassanes (Barcelona, Spain) from January 2009 to December 2020. Epidemiological and clinical characteristics from included patients were collected. RESULTS: Overall, 865 cases of imported strongyloidiasis were diagnosed, of whom 472 (54.6 %) were men and mean age was 38.7 (SD 13.4) years. Most cases were diagnosed in migrants (830, 96 %). The distribution of the geographic origin was: Latin America (561, 67.6 %), Sub-Saharan Africa (148, 17.8 %), Asia (113, 13.6 %), North Africa (5, 0.6 %), Eastern Europe (2, 0.2 %), and North America (1, 0.1 %). The main reasons for consultation at the Unit were screening of health status (371, 42.9 %), laboratory test alteration (367, 42.4 %), gastrointestinal symptoms (56, 6.5 %), cutaneous symptoms (26, 3 %), and other clinical symptoms (45, 5.2 %). An increase in the number of cases was observed in the last years of the study period. CONCLUSIONS: Imported strongyloidiasis has increasingly been diagnosed in our referral unit, mostly due to screening strategies implementation. Most of the patients were young migrants coming from Latin America, with no symptoms at the time of diagnosis. The optimization of screening strategies will increase the detection and treatment of cases, reducing potential complications.


Subject(s)
Emigrants and Immigrants , Strongyloides stercoralis , Strongyloidiasis , Male , Animals , Humans , Adult , Female , Strongyloidiasis/diagnosis , Strongyloidiasis/epidemiology , Strongyloidiasis/complications , Spain/epidemiology , Retrospective Studies , Global Health , Referral and Consultation
4.
Eur J Med Res ; 28(1): 281, 2023 Aug 11.
Article in English | MEDLINE | ID: mdl-37563592

ABSTRACT

BACKGROUND: Fatal forms of strongyloidiasis, hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS), are caused by exaggerated autoinfection of the intestinal nematode, Strongyloides stercoralis (S. stercoralis). Corticosteroids, frequently administered to patients with severe COVID-19, can transform chronic asymptomatic strongyloidiasis into the above-mentioned fatal diseases. This study aimed to investigate the prevalence of strongyloidiasis in COVID-19 patients receiving corticosteroids in a hypoendemic region. METHODS: The present cross-sectional study enrolled 308 COVID-19 patients admitted to two hospitals in Ahvaz and Abadan in the southwest of Iran between 2020 and 2022. A real-time reverse transcription polymerase chain reaction (RT-PCR) test and chest computed tomography (CT) scan were employed to detect and monitor the disease's severity in the patients, respectively. All patients were evaluated for IgG/IgM against S. stercoralis using Enzyme-linked immunosorbent assay (ELISA) test. Subsequently, individuals with a positive ELISA test were confirmed using parasitological methods, including direct smear and agar plate culture (APC). RESULTS: The patients were between 15 and 94 years old, with a mean age of 57.99 ± 17.4 years. Of the 308 patients, 12 (3.9%) had a positive ELISA test, while 296 (96.1%) had negative results. Three of the 12 patients with a positive ELISA result died, and three failed to provide a stool sample. To this end, only six cases were examined parasitologically, in which S. stercoralis larvae were observed in five patients. Significant differences were found between S. stercoralis infection with sex (p = 0.037) and age (p = 0.027). Binary regression analysis revealed that strongyloidiasis was positively associated with sex (odds ratio [OR]: 5.137; 95% confidence interval [CI]: 1.107-23.847), age (OR: 5.647; 95% CI 1.216-26.218), and location (OR: 3.254; 95% CI: 0.864-12.257). CONCLUSIONS: Our findings suggest that screening for latent strongyloidiasis in COVID-19 patients in endemic areas using high-sensitivity diagnostic methods, particularly ELISA, before receiving suppressive drugs should be given more consideration.


Subject(s)
COVID-19 , Coinfection , Strongyloidiasis , Humans , Adult , Middle Aged , Aged , Adolescent , Young Adult , Aged, 80 and over , Strongyloidiasis/complications , Strongyloidiasis/epidemiology , Strongyloidiasis/diagnosis , Prevalence , Coinfection/complications , Cross-Sectional Studies , COVID-19/complications , COVID-19/epidemiology , Adrenal Cortex Hormones
5.
BMJ Case Rep ; 16(8)2023 Aug 29.
Article in English | MEDLINE | ID: mdl-37643819

ABSTRACT

Strongyloidiasis, a helminth infection caused by Strongyloides stercoralis, can be complicated by hyperinfection, especially in the setting of immunosuppression; however, many patients go undiagnosed. One clue to diagnosis is unexplained gram-negative bacteraemia or meningitis in patients who are immunosuppressed. Serology can be helpful but may be negative in these patients who are immunocompromised.We present the case of a white cisgender man from Central America in his 40s, living with HIV, with a CD4 count of 77 cells/µL. He was diagnosed with Strongyloides hyperinfection after an increase in his steroid dose. He also had Escherichia coli meningitis and bacteraemia. Strongyloidiasis was diagnosed by stool microscopy despite a negative serology test.This case highlights the challenges in diagnosing strongyloidiasis in the setting of immunosuppression. A high index of clinical suspicion is warranted for patients living with HIV on high-dose corticosteroids. Up to three stool microscopy studies for Strongyloides should be sent in addition to serology.


Subject(s)
Bacteremia , HIV Infections , Meningitis, Escherichia coli , Strongyloides stercoralis , Strongyloidiasis , Male , Animals , Humans , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Bacteremia/drug therapy , HIV Infections/complications
6.
BMJ Case Rep ; 16(8)2023 Aug 27.
Article in English | MEDLINE | ID: mdl-37640414

ABSTRACT

A woman in her 50s with a medical history of cirrhosis, alcohol use disorder, primary biliary cholangitis and extended spectrum beta lactamase (ESBL) Klebsiella presented with weakness, cough and abdominal pain with positive blood cultures for ESBL Klebsiella, and was treated with intravenous meropenem and patient symptoms improved. Testing for Strongyloides antibodies was positive, so she was treated with ivermectin. Strongyloidiasis-associated Gram-negative rod (GNR) bacteremia are rare conditions; however, it is important to consider an underlying strongyloidiasis in recurrent GNR bacteremia to prevent recurrent hospitalisation and morbidity.


Subject(s)
Bacteremia , Hepatopulmonary Syndrome , Strongyloidiasis , Female , Humans , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Bacteremia/complications , Bacteremia/drug therapy , Hydrolases , Klebsiella , Liver Cirrhosis/complications
7.
Infection ; 51(5): 1541-1548, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37462896

ABSTRACT

PURPOSE OF THE STUDY: We assessed the prevalence of S. stercoralis in a cohort of inpatients with invasive bacterial infections of enteric origin to investigate whether the parasite may facilitate these bacterial infections even in the absence of larval hyperproliferation. METHODS: We performed a prospective cross-sectional study in a hospital in northern Italy. Subjects admitted due to invasive bacterial infection of enteric origin and potential previous exposure to S. stercoralis were systematically enrolled over a period of 10 months. S. stercoralis infection was investigated with an in-house PCR on a single stool sample and with at least one serological method (in-house IFAT and/or ELISA Bordier). Univariate, bi-variate and logistic regression analyses were performed. RESULTS: Strongyloidiasis was diagnosed in 14/57 patients (24.6%; 95% confidence interval 14.1-37.8%) of which 10 were Italians (10/49, 20.4%) and 4 were migrants (4/8, 50.0%). Stool PCR was performed in 43/57 patients (75.4%) and no positive results were obtained. Strongyloidiasis was found to be significantly associated (p ≤ 0.05) with male gender, long international travels to areas at higher endemicity, deep extra-intestinal infectious localization and solid tumors. In the logistic regression model, increased risk remained for the variables deep extra-intestinal infectious localization and oncologic malignancy. CONCLUSIONS: Our findings suggest a new role of chronic strongyloidiasis in favoring invasive bacterial infections of enteric origin even in the absence of evident larval dissemination outside the intestinal lumen. Further well-designed studies should be conducted to confirm our results, and possibly establish the underlying mechanisms.


Subject(s)
Bacterial Infections , Strongyloides stercoralis , Strongyloidiasis , Animals , Humans , Male , Strongyloidiasis/complications , Strongyloidiasis/epidemiology , Strongyloidiasis/diagnosis , Cross-Sectional Studies , Tertiary Care Centers , Prospective Studies , Feces/parasitology
9.
Korean J Gastroenterol ; 81(6): 270-275, 2023 06 25.
Article in English | MEDLINE | ID: mdl-37350523

ABSTRACT

Strongyloidiasis, a chronic helminth infection caused by the parasitic nematode Strongyloides stercoralis, has various clinical manifestations. Although rare, duodenal obstructions and venous thromboembolism are possible complications of strongyloidiasis. This paper presents the case of a 47-year-old Vietnamese male with a history of right lower limb edema, anorexia, nausea, vomiting, diarrhea, and abdominal discomfort lasting for four months. Venous Doppler ultrasound detected a thrombus in the right femoral vein, while an abdominal CT scan revealed a mass lesion suggestive of a lower bile duct tumor. Esophageogastroduodenoscopy showed a friable duodenal cap mucosa with multiple ulcers and edematous mucosa of the second part of the duodenum that caused a partial lumen obstruction. The final histological examination of the biopsy specimen revealed chronic duodenitis with larvae consistent with Strongyloides stercoralis. The patient was treated with Ivermectin for two weeks and anticoagulation therapy for three months. After treatment and a six-month follow-up, the patient's gastrointestinal symptoms and leg swelling resolved completely. This is the first documented case of a patient in Vietnam with strongyloidiasis who presented with venous thromboembolism and duodenal obstruction.


Subject(s)
Duodenal Obstruction , Strongyloides stercoralis , Strongyloidiasis , Venous Thromboembolism , Male , Humans , Middle Aged , Animals , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Venous Thromboembolism/diagnosis , Venous Thromboembolism/drug therapy , Venous Thromboembolism/etiology , Vietnam , Ivermectin/therapeutic use
10.
Am J Trop Med Hyg ; 109(2): 332-334, 2023 08 02.
Article in English | MEDLINE | ID: mdl-37364861

ABSTRACT

Strongyloides stercoralis infection is a common infection in tropical and subtropical regions and is considered one of the "neglected tropical diseases." Owing to its life cycle, this infection can remain undetectable for years, preventing an early diagnosis and prompt treatment. We report the case of a 65-year-old woman who presented to us with a history of nausea, abdominal pain, bloating, and weight loss and, after initial radiologic and laboratory workup, was diagnosed with a periampullary mass with no secondary spread. She underwent an uneventful pylorus-preserving pancreatoduodenectomy, and on histopathological study of the lesion, a diagnosis of S. stercoralis infection was confirmed. This case stands out because of the importance of keeping S. stercoralis infections as a differential diagnosis of periampullary masses, particularly when the patient comes from regions where S. stercoralis is prevalent.


Subject(s)
Duodenal Diseases , Strongyloides stercoralis , Strongyloidiasis , Duodenal Diseases/etiology , Constriction, Pathologic/etiology , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Humans , Female , Aged
11.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi ; 35(2): 206-212, 2023 Apr 26.
Article in Chinese | MEDLINE | ID: mdl-37253572

ABSTRACT

Strongyloides stercoralis is an opportunistic pathogenic parasite that can cause severe strongyloidiasis and even death among immunocompromised individuals. Previous clinical studies have reported cases co-infected with S. stercoralis and other pathogens, such as parasites, viruses, bacteria and fungi. This review summarizes strongyloidiasis patients co-infected with pathogens, and analyzes the impact of co-infection on strongyloidiasis, so as to provide insights into the reduction of the morbidity and mortality of disorders associated with S. stercoralis infections.


Subject(s)
Coinfection , Strongyloides stercoralis , Strongyloidiasis , Animals , Humans , Strongyloidiasis/complications , Immunocompromised Host
12.
JNMA J Nepal Med Assoc ; 61(257): 80-83, 2023 Jan 01.
Article in English | MEDLINE | ID: mdl-37203926

ABSTRACT

Strongyloidiasis, a parasitic infestation by Strongyloides stercoralis, involves the gastrointestinal tract with a spectrum from duodenitis to enterocolitis. However, gastric involvement with the manifestation of upper gastrointestinal bleeding is an extremely rare condition due to Strongyloides stercoralis. Due to irregular excretion of larvae, unclear symptoms, paucity of effective diagnostic tools and low parasitic load, makes clinicians difficult to reach the diagnosis of strongyloidiasis. Here, we present a case of upper gastrointestinal bleeding due to a large gastric ulcer whose aetiology was identified to be Strongyloides stercoralis infection of the gastric region by the diagnosis of exclusion. Keywords: gastric ulcer; gastrointestinal haemorrhage; Strongyloides stercoralis; strongyloidiasis.


Subject(s)
Stomach Ulcer , Strongyloides stercoralis , Strongyloidiasis , Animals , Humans , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/parasitology , Stomach Ulcer/complications , Stomach Ulcer/diagnosis , Stomach Ulcer/parasitology , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology
14.
Curr Opin Infect Dis ; 36(3): 203-208, 2023 06 01.
Article in English | MEDLINE | ID: mdl-37093059

ABSTRACT

PURPOSE OF REVIEW: Strongyloidiasis is a soil-transmitted helminthiasis, a neglected tropical disease that affects 300-900 million individuals globally. Strongyloides stercoralis is associated with cutaneous, respiratory, and gastrointestinal clinical manifestations. Chronicity is due to an autoinfective cycle, and host immunosuppression can lead to severe and fatal disease. Lung involvement is significant in severe strongyloidiasis, and Strongyloides has a complex association with a number of lung diseases, which will be discussed in this review. RECENT FINDINGS: The treatment of chronic lung diseases such as asthma and chronic obstructive pulmonary disease with corticosteroids is an important risk factor for Strongyloides hyperinfection syndrome (SHS)/disseminated strongyloidiasis. The use of corticosteroids in the treatment of coronavirus disease 2019 (COVID-19) and potentially COVID-19-induced eosinopenia are risk factors for severe strongyloidiasis. Recent findings have demonstrated a significant immunomodulatory role of Strongyloides in both latent and active pulmonary tuberculosis associated to an impaired immune response and poor outcomes in active pulmonary tuberculosis. SUMMARY: Strongyloides lung involvement is a common finding in severe infection. Prompt recognition of Strongyloides infection as well as prevention of severe disease by screening or presumptive treatment are important goals in order to improve Strongyloides outcomes in at-risk population.


Subject(s)
COVID-19 , Strongyloides stercoralis , Strongyloidiasis , Tuberculosis, Pulmonary , Animals , Humans , Strongyloidiasis/complications , Strongyloidiasis/drug therapy , Strongyloidiasis/epidemiology , COVID-19/complications , Lung , Tuberculosis, Pulmonary/complications
17.
New Microbiol ; 46(1): 86-89, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36853825

ABSTRACT

Strongyloidiasis is a gastrointestinal parasitic infection caused by percutaneous infection with Strongyloides stercoralis, which is mainly distributed in the tropics and subtropics worldwide. Digestive symptoms like diarrhea and abdominal pain are the main manifestation, but serious infections such as bacterial pneumonia, purulent meningitis and sepsis also occur in immunocompromised individuals. Herein, we present a rare case of a type II diabetes mellitus (T2DM) patient presented with gastrointestinal hemorrhage and sepsis caused by concomitant Strongyloides stercoralis and cytomegalovirus (CMV) infection. This 51-year-old male patient presented to the hospital with vomiting, diarrhea, dyspnea, palpitation and weakness. Examination revealed skin soft-tissue infection with T2DM, and upper endoscopy revealed gastric mucosal erosion and hemorrhage. Radiology revealed bilateral diffuse interstitial infiltrates and thickened walls of the colon. Importantly, stool and vomitus examination showed numerous larvae of Strongyloides stercoralis. Then the diagnosis of Strongyloides hyperinfection syndrome was made. But antibiotics and albendazole treatment did not improve the patient's symptoms of gastrointestinal bleeding and sepsis. Subsequently, other pathogens were screened by sequence and a positive CMV gene was found in the peripheral blood. Thus, antibiotics, albendazole and ganciclovir were all used which ultimately resolved the infection in this patient. Therefore, this case indicated CMV could also by co-infected with Strongyloides stercoralis in the immunocompromised patient, which remind us that an CMV test should also be performed when encountered in severe strongyloidiasis infection, which could improve the prognosis of the patient.


Subject(s)
Cytomegalovirus Infections , Diabetes Mellitus, Type 2 , Sepsis , Strongyloides stercoralis , Strongyloidiasis , Male , Animals , Humans , Middle Aged , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Diabetes Mellitus, Type 2/complications , Albendazole/therapeutic use , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/drug therapy , Anti-Bacterial Agents , Diarrhea
19.
Mod Rheumatol Case Rep ; 7(1): 113-116, 2023 01 03.
Article in English | MEDLINE | ID: mdl-36264196

ABSTRACT

Strongyloidiasis, an intestinal parasitic infection caused by Strongyloides stercoralis, rarely occurs in Japan. When treated with immunosuppressive drugs, two potentially lethal conditions, hyperinfection and dissemination, may develop in asymptomatic carriers of this parasite. We report the development of strongyloidiasis during treatment of polymyositis with glucocorticoids plus rituximab (RTX). A 44-year-old woman had been diagnosed with anti-signal recognition particle antibody-positive polymyositis with interstitial pneumonia 6 years previously, for which she had recently been receiving prednisolone at 5 mg/day and RTX at 375 mg/m2 twice every 3 months. Her condition appeared to be well controlled. She was admitted to our hospital with a 1-month history of chronic diarrhoea and epigastric pain. Standard microscopic examination of a sample of faeces revealed the presence of S. stercoralis; however, serologic testing for parasites was negative. Treatment with ivermectin alleviated her inflammatory diarrhoea and eradicated the faecal parasites. We believe that our patient had an exacerbation of S. stercoralis infection (hyperinfection syndrome) that was exacerbated by low-dose glucocorticoids plus RTX. Strongyloidiasis should be considered in immunocompromised individuals with unexplained diarrhoea, even in non-endemic areas.


Subject(s)
Polymyositis , Strongyloides stercoralis , Strongyloidiasis , Animals , Female , Humans , Adult , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Glucocorticoids/therapeutic use , Rituximab/therapeutic use
20.
Rev Esp Enferm Dig ; 115(2): 102-103, 2023 02.
Article in English | MEDLINE | ID: mdl-35815784

ABSTRACT

We herein report a case of ulcerative colitis (UC) exacerbated by strongyloidiasis. Parasites including Strongyloides stercoralis and Entamoeba histolytica can cause chronic gastrointestinal inflammation and long-lasting symptoms resembling UC. On the other hand, it is not well-known that such organisms can trigger the exacerbation of pre-existing UC. We would like to highlight the importance of recognition of strongyloidiasis in the management of UC patients who have lived in or migrated from endemic regions, such as Asia, Africa, and South America.


Subject(s)
Colitis, Ulcerative , Strongyloides stercoralis , Strongyloidiasis , Animals , Humans , Strongyloidiasis/complications , Strongyloidiasis/diagnosis , Strongyloidiasis/epidemiology , Colitis, Ulcerative/complications , Inflammation
SELECTION OF CITATIONS
SEARCH DETAIL
...